User:Mr. Ibrahem/Osimertinib

Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung cancer (NSCLC) with certain mutations in the EGFR gene. It is taken by mouth.

Common side effects include diarrhea, rash, sore mouth, tiredness, and liver inflammation. Other side effects may include pneumonitis, QT prolongation, cardiomyopathy, and eye inflammation. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor.

Osimertinib was approved for medical use in the United States in 2015 and in Europe in 2016. In the United Kingdom it costs the NHS about £5,800 per month as of 2021. In the United States this amount costs about 16,000 USD.